ANIP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ANI Pharmaceuticals Inc (ANIP) is not a strong buy at this moment for a beginner investor with a long-term strategy. While there are some positive catalysts, such as the launch of a new product with exclusivity and strong revenue growth, the significant drop in net income and EPS, coupled with neutral technical indicators and lack of strong trading signals, suggests that this stock is better suited for monitoring rather than immediate investment.
The MACD is positive but contracting, RSI is neutral at 43.869, and moving averages are converging, indicating no clear trend. Support is at 76.611, and resistance is at 81.612. The stock is trading near its support level, but there is no strong bullish signal.
ANI Pharmaceuticals launched Pimozide Tablets with 180-day CGT exclusivity, which is expected to reduce competition and generate approximately $3.1 million in annual sales. Revenue increased by 29.64% YoY in the latest quarter.
Net income dropped significantly by -337.66% YoY, and EPS fell by -309.09% YoY in the latest quarter. The stock experienced a -2.60% decline in the last trading session, and there is no strong trading sentiment from hedge funds, insiders, or options data.
In Q4 2025, revenue increased by 29.64% YoY to $247.06 million, but net income dropped by -337.66% YoY to $25.39 million. EPS fell to 1.15, down -309.09% YoY. Gross margin improved to 50.26%, up 9.21% YoY.
No recent analyst rating or price target changes available.
